Comparison of Otoacoustic Emissions in Asymptomatic Diabetes Mellitus and Normal Hearing Control Groups

Suwimol Ruencharoen; Chanchai Jariengprasert; Montip Tiensuwan; Chardpraorn Ngarmukos

doi:10.33165/rmj.2019.42.2.139031

Authors

Suwimol Ruencharoen Department of Communication Sciences and Disorders, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
Chanchai Jariengprasert Department of Otolaryngology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
Montip Tiensuwan Department of Mathematics, Faculty of Science, Mahidol University, Bangkok, Thailand
Chardpraorn Ngarmukos Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

DOI:

https://doi.org/10.33165/rmj.2019.42.2.139031

Keywords:

Diabetes mellitus, Otoacoustic emissions, Sensorineural hearing loss

Abstract

Background: Diabetes mellitus (DM) is a chronic metabolic disorder. Previous studies reported the hearing impairment of diabetes patients as a progressive bilateral symmetrical sensorineural hearing loss (SNHL) of gradual onset which predominantly affected the higher frequencies, and found that diabetic patients had unsatisfactory hearing thresholds than nondiabetics in the same age group. For the use of evoked otoacoustic emissions (EOAEs) as a clinical test of hearing, EOAEs are sound which can be recorded in the outer ear canal and give objective information about preneural, mechanical elements of the cochlear function.

Objective: To compare the otoacoustic emissions of asymptomatic DM patients with a normal hearing control group.

Methods: All subjects received a routine audiologic evaluation which consisted of pure-tone air-bone conduction tests, tympanograms, and stapedius acoustic reflex tests. OAEs were measured in 30 asymptomatic diabetic patients with a mean age of 55.73 years and an age-matched 30 subjects normal hearing control group with a mean age of 50.87 years.

Results: The pure-tone thresholds at 3, 4, 6, and 8 kHz; transient-evoked otoacoustic emissions (TEOAEs) amplitudes at 1, 1.5, 2, and 3 kHz; and the distortion product otoacoustic emissions (DPOAEs) amplitudes at 1, 1.5, 2, 3, 4, and 6 kHz were significantly different (P < .05) between the asymptomatic and control groups.

Conclusions: This study suggested that diabetic patients had a significant hearing impairment. SNHL is gradually progressive and is a common condition in DM patients and their thresholds for hearing are higher at higher frequencies.

References

Nathan DM. The pathophysiology of diabetic complications: how much does the glucose hypothesis explain? Ann Intern Med. 1996;124(1 Pt 2):86-89.

Young RJ, Macintyre CC, Martyn CN, et al. Progression of subclinical polyneuropathy in young patients with type 1 (insulin-dependent) diabetes: associations with glycaemic control and microangiopathy (microvascular complications). Diabetologia. 1986;29(3):156-161.

Axelsson A, Fagerberg SE. Auditory function in diabetics. Acta Otolaryngol. 1968;66(1):49-64.

Jorgensen MB, Buch NH. Studies on inner-ear function and cranial nerves in diabetics. Acta Otolaryngol. 1961;53:350-364.

Taylor IG, Irwin J. Some audiological aspects of diabetes mellitus. J Laryngol Otol. 1978 ;92(2):99-113.

Gibbin KP, Davis CG. A hearing survey in diabetes mellitus. Clin Otolaryngol Allied Sci. 1981;6(5):345-350. doi:10.1111/j.1365-2273.1981.tb01809.x.

Miller JJ, Beck L, Davis A, Jones DE, Thomas AB. Hearing loss in patients with diabetic retinopathy. Am J Otolaryngol. 1983;4(5):342-346. doi:10.1016/S0196-0709(83)80021-0.

Kasemsuwan L, Sriwanyong S, Krittiyawong S, Sunetrworakul J, Jiamsuchon K. Hearing in young diabetic patients. J Med Assoc Thai. 2001;84(10):1389-1394.

Ferrer JP, Biurrun O, Lorente J, et al. Auditory function in young patients with type 1 diabetes mellitus. Diabetes Res Clin Pract. 1991;11(1):17-22. doi:10.1016/0168-8227(91)90136-2.

Tay HL, Ray N, Ohri R, Frootko NJ. Diabetes mellitus and hearing loss. Clin Otolaryngol Allied Sci. 1995;20(2):130-134. doi:10.1111/j.1365-2273.1995.tb00029.x.

Virtaniemi J, Laakso M, Nuutinen J, Karjalainen S, Vartiainen E. Hearing thresholds in insulin-dependent diabetic patients. J Laryngol Otol. 1994;108(10):837-841.

Simoncelli C, Ricci G, Molini E, et al. Evoked acoustic oto-emissions in patients with diabetes mellitus. Ann Otolaryngol Chir Cervicofac. 1993;110(5):255-258.

Di Leo MA, Di Nardo W, Cercone S, et al. Cochlear dysfunction in IDDM patients with subclinical peripheral neuropathy. Diabetes Care. 1997;20(5):824-828.

Erdem T, Ozturan O, Miman MC, Ozturk C, Karatas E. Exploration of the early auditory effects of hyperlipoproteinemia and diabetes mellitus using otoacoustic emissions. Eur Arch Otorhinolaryngol. 2003;260(2):62-66. doi:10.1007/s00405-002-0519-1.

Rimm EB, Chan J, Stampfer MJ, Colditz GA, Willett WC. Prospective study of cigarette smoking, alcohol use, and the risk of diabetes in men. BMJ. 1995;310(6979):555-559. doi:10.1136/bmj.310.6979.555.

Pulec JL, Pulec MB, Mendoza I. Progressive sensorineural hearing loss, subjective tinnitus and vertigo caused by elevated blood lipids. Ear Nose Throat J. 1997;76(10):716-720, 725-726, 728 passim.

Bray PJ. A Study of the Properties of Click Evoked Otoacoustic Emissions and Development of a Clinical Otoacoustic Hearing Test Instrument [dissertation]. London: University College and Middlesex School of School of Medicine; 1989.

Hauser R, Probst R. The influence of systematic primary-tone level variation L2-L1 on the acoustic distortion product emission 2f1-f2 in normal human ears. J Acoust Soc Am. 1991;89(1):280-286.

Sun XM, Jung MD, Kim DO, Randolph KJ. Distortion product otoacoustic emission test of sensorineural hearing loss in humans: comparison of unequal- and equal-level stimuli. Ann Otol Rhinol Laryngol. 1996;105(12):982-990.

Kemp DT, Ryan S, Bray P. A guide to the effective use of otoacoustic emissions. Ear Hear. 1990;11(2):93-105.

Vedantam R, Musiek FE. Click evoked otoacoustic emissions in adult subjects: standard indices and test-retest reliability. Am J Otol. 1991;12(6):435-442.

Lonsbury-Martin BL, Harris FP, Stagner BB, Hawkins MD, Martin GK. Distortion product emissions in humans. I. Basic properties in normally hearing subjects. Ann Otol Rhinol Laryngol Suppl. 1990;147:3-14.

Edgar TO. Klinische Untersuchungen uber die Erkrankungen des Gehororgans bei Diabetes Mellitus mit besonderer Berucksichtigung der Erkrankungen des inneren Ohres. Mschr Ohrenheilk LaryngoRhinol. 1915;49:225-260.

Cullen JR, Cinnamond MJ. Hearing loss in diabetics. J Laryngol Otol. 1993;107(3):179-182.

Weng SF, Chen YS, Hsu CJ, Tseng FY. Clinical features of sudden sensorineural hearing loss in diabetic patients. Laryngoscope. 2005;115(9):1676-1680.

Robinson DW. Threshold of hearing as a function of age and sex for the typical unscreened population. Br J Audiol. 1988;22(1):5-20.

Di Nardo W, Ghirlanda G, Paludetti G, et al. Distortion-product otoacoustic emissions and selective sensorineural loss in IDDM. Diabetes care. 1998;21(8):1317-1321.

Avan P, Bonfils P, Loth D, Teyssou M, Trotoux J, Narcy P. Study of the cochlea by evoked otoemissions. Physiological interpretation of results. Ann Otolaryngol Chir Cervicofac. 1991;108(3):135-141.

Kemp DT. Otoacoustic emissions, travelling waves and cochlear mechanisms. Hear Res. 1986;22: 95-104. doi:10.1016/0378-5955(86)90087-0.

Moulin A, Bera JC, Collet L. Distortion product otoacoustic emissions and sensorineural hearing loss. Audiology. 1994;33(6):305-226.